nmsg

Dai laboratori di Nerviano Medical Sciences nuovi dati presentati all’AACR meeting di Philadelphia

Nerviano,  18 Marzo 2015 - All’appuntamento annuale dell’American Association for Cancer Research (AACR) che si svolgerà ad aprile, Nerviano Medical Sciences presenterà nuove evidenze dalle attività di ricerca condotte sui cordomi e su nuovi diversi inibitori.

Di seguito i dettagli degli abstract (disponibili al sito http://www.aacr.org) e dell’oral presentation prevista per lunedì 20:

Presentation title: Establishment and characterization of the new sacral chordoma cell line Chor-IN-1
Authors: Paola Magnaghi et al
Meeting: AACR Annual Meeting 2015, Abstract number 74
Presentation Time: Sunday, Apr 19, 2015, 1:00 PM - 5:00 PM


Presentation Title: NMS-P088, a dual FLT3-KIT inhibitor active also on gatekeeper mutations and devoid of QTc prolongation
Authors: Ciomei, M et al
Meeting: AACR Annual Meeting 2015, Abstract number 798
Presentation Time: Sunday, Apr 19, 2015, 1:00 PM - 5:00 PM


Presentation title: Preclinical characterization of the novel TTK kinase inhibitor S81694 for the treatment of triple negative breast cancer
Authors: Riccardo Colombo et al
Meeting: AACR Annual Meeting 2015, Abstract number 1638
Presentation Time: Monday, Apr 20, 2015, 8:00 AM -12:00 PM


Presentation title: Preclinical characterization of NMS-P648, a novel and potent PARP-1/-3 inhibitor
Authors: Alessia Montagnoli et al
Meeting: AACR Annual Meeting 2015, Abstract number 2851
Presentation Time: Monday, Apr 20, 2015, 3:50 PM - 4:05 PM


The last poster has been selected for an oral presentation:
Session title: PARP and DNA Repair Inhibitors
Session type: Minisymposium
Session Start/End Time: Monday, Apr 20, 2015, 3:00 PM - 5:00 PM
Location: Room 108, Pennsylvania Convention Center

 
Per offrirti un'esperienza di navigazione ottimizzata NMS Group e le società controllate utilizzano cookies, anche di terze parti.
Proseguendo con la navigazione acconsenti al loro impiego in conformità della nostra  
Cookie Policy.